Calidi Biotherapeutics, Inc. (CLDI): Prakiraan volume dodolan
High technological barriers and GMP standards protect the developments of Calidi Biotherapeutics (CLDI), confirming the level of the company's projected sales. The current status is 0.00, although the risk of secondary offerings and biomaterial costs are creating pressure. Meanwhile, a progressive image within the oncology environment and confidence in the viral platform sustain optimism among long-term asset holders.
Calidi Bio (CLDI) - rincian metrik lan laporan keuangan
- kuotasi lan prakiraan analis:
- data kapitalisasi bursa:
- informasi kapitalisasi buku:
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal Calidi Biotherapeutics|CLDI - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Calidi Biotherapeutics|CLDI - Gunggung kewajiban utang perusahaan|Utang marang nilai buku Calidi Biotherapeutics Inc.|CLDI - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Calidi Biotherapeutics|Rasio cepet calidibio.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
CLDI - Asil keuangan resik|Bathi sing dikarepake Calidi Biotherapeutics|CLDI - Kapitalisasi marang bathi|Prakiraan rega marang bathi Calidi Biotherapeutics|CLDI - Rasio nilai perusahaan marang wutah bathi|Pangali EV/EBITDA Calidi Biotherapeutics Inc.|CLDI - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Calidi Biotherapeutics|CLDI - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan calidibio.com|CLDI - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Calidi Biotherapeutics
- rincian pendapatan lan dodolan emiten:
Analisis dhasar perusahaan:Calidi Biotherapeutics, Inc. CLDI
This indicator measures revenue generation potential by assessing the fundamental resilience of the business amid market volatility. The metric tracks the alignment of operational performance with the investment mandate through daily risk monitoring. For Calidi Biotherapeutics (CLDI), the company's promising sales momentum reflects the monetization of its proprietary viral delivery technologies. However, capital requirements for R&D may create short-term deviations. Analysis of this chart allows for balancing technological optimism with actual portfolio liquidity.
Pesaing langsung
Prakiraan volume dodolan ONC|Volume dodolan mangsa ngarep perusahaan halozyme.com HALO|Prakiraan volume dodolan RVMD (Revolution Medicines, Inc.)|Prakiraan volume dodolan Ascentage Pharma Group International AAPG|CGON - Prakiraan pendapatan perusahaan|URGN: Prakiraan pendapatan perusahaan|BCAX: Prakiraan volume dodolan|PSNL - Dodolan mangsa ngarep perusahaan|ERAS (Erasca) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan DCTH (Delcath Systems Inc)|Prakiraan volume dodolan YMAB|Dodolan mangsa ngarep perusahaan Aura Corp|Candel Therapeutics, Inc. - Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan ARAY|SELLAS Life Sciences Group Inc. - Prakiraan volume dodolan|ACTU: Prakiraan pendapatan perusahaan|CTOR: Prakiraan volume dodolan|HURA - Dodolan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan Protara Therapeutics|Volume dodolan sing dikarepake perusahaan fatetherapeutics.com FATE|Volume dodolan mangsa ngarep perusahaan WHWK (Aadi Bioscience Inc)|Prakiraan volume pendapatan perusahaan TCRX|Prakiraan volume dodolan CSBR (Champions Oncology, Inc.)|Pendapatan mangsa ngarep perusahaan XBIT|CEL-SCI Corp - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan ostherapies.com|Radiopharm Theranostics (RADX) - Prakiraan pendapatan perusahaan|Artiva Biotherapeutics - Pendapatan mangsa ngarep perusahaan|ANL (Adlai Nortye Ltd) - Prakiraan volume dodolan|Prakiraan volume dodolan Veru Corporation|Prakiraan pendapatan perusahaan Tempest Therapeutics (TPST)|XLO: Pendapatan sing dikarepake perusahaan|Prakiraan volume dodolan RENB (Renovaro)|Mural Oncology PLC (MURA) - Volume dodolan sing dikarepake perusahaan|KAPA: Volume dodolan mangsa ngarep perusahaan|OKUR - Prakiraan volume dodolan|GDTC (w2.cytomed.sg) - Volume dodolan mangsa ngarep perusahaan|CRIS: Prakiraan volume pendapatan perusahaan|APLM (Apollomics Inc.) - Prakiraan volume dodolan|Tharimmune Inc (THAR) - Dodolan mangsa ngarep perusahaan|Prakiraan volume dodolan ADVB|Volume dodolan mangsa ngarep perusahaan Genprex Inc GNPX|Prakiraan pendapatan perusahaan Sunshine Biopharma SBFM|Dodolan mangsa ngarep perusahaan Xenetic Biosciences Inc. (XBIO)|Salarius Pharmaceuticals, Inc. - Prakiraan volume dodolan|Purple Biotech Ltd (PPBT) - Volume dodolan mangsa ngarep perusahaan|aoncology.com (AONC) - Prakiraan pendapatan perusahaan|BGNE (BeiGene Ltd) - Prakiraan pendapatan perusahaan|CKPT (Checkpoint Therapeutics) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan ELEV (Elevation Oncology Inc.)|Prakiraan volume dodolan ICAD|Dodolan mangsa ngarep perusahaan ikenaoncology.com|Prakiraan volume dodolan NTBL (Notable Labs Inc.)|VIRX - Volume dodolan mangsa ngarep perusahaan|MorphoSys AG - Prakiraan volume dodolan|NAYA - Prakiraan volume dodolan|Ascentage Pharma (AAPGV) - Prakiraan pendapatan perusahaan
